Delivering affordable biologics from gene to vial

BioProcess International

Volumn 8, Issue 3, 2010, Pages 16-19

  Sinclair, Andrew ^a   Monge, Miriam ^b  

^a BioPharm Services UK   (United Kingdom)

^b Biopharm Services   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; MONOCLONAL ANTIBODY; RIBOSOME DNA;

BIOLOGICAL THERAPY; BIOPROCESS; BIOTECHNOLOGICAL PROCEDURES; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DRUG INDUSTRY; HEALTH CARE COST; HEALTH CARE QUALITY; MEDICAL PRACTICE; REVIEW;

EID: 77953456236     PISSN: 15426319     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Review

References (16)

1. Total Global Biopharmaceutical Market Estimated to be Around $89.7 Billion, of Which the MAb Products Are a Key Component. Beyond Borders: Global Biotechnology Report 2009. Ernst & Young: New York, NY, May 2009.
2. The Global Alliance for Vaccines and Immunisation: Geneva, Switzerland; www.gavialliance.org.
3. GAVI's Impact on Vaccine Market Is Bringing Down Prices. The Global Alliance for Vaccines and Immunisation: Geneva, Switzerland, 18 November 2009; www.gavialliance.org/media-centre/press-releases/2009-11-18-vaccine- market-impact.php.
4. Coopers & Lybrand A Modern Smokestack Industry. The Economist 14 November 1992.
5. A Survey of the Use of Biotechnology in US Industry. U.S. Department of Commerce: Washington, DC, 2003; www.technology.gov/reports/ Biotechnology/CD120a-0310.pdf.
6. New Drug Output Continues to Stagnate, While R&D Costs Remain High. Outlook 2009. Tufts Center for the Study of Drug Development: Boston, MA, 2009; http://csdd.tufts.edu/InfoServices/OutlookPDFs/Outlook2009.pdf.
7. Berenson A. A Cancer Drug Shows Promise, at a Price That Many Can't Pay. The New York Times 15 February 2006: www.nytimes.com/2006/02/15/business/ 15drug.html.
8. Krumholz HM, Ross JS. Relationships with the Drug Industry: More Regulation, Greater Transparency. BMJ 3 February 2009: 338:b211; www.bmj.com/cgi/content/extract/338/feb03-2/b211.
9. Rawlins M. NICE Chairman Hits Back at Critics. Health Service J. 18 August 2008; www.hsj.co.uk/news/2008/08/nice-chairman-hits-back-at-critics. html.
10. Hawkes N. NICE Goes Global. BMJ 28 January 2009: 338:b103; www.bmj.com/cgi/content/extract/338/jan28-2/b103.
11. Roebers JR. Future Trends in Biopharmaceutical Operations and Facilities. Presented at BioProcess International Conference and Exhibition, Raleigh, NC, 12-16 October 2009. IBC Life Sciences: Westborough, MA; www.ibclifesciences.com/bpi.
12. Jagschies G. Flexible Manufacturing: The New Driver in Monoclonal Antibody Process Economics. GE Healthcare Webinar, 18 February 2009.
13. Biogen Idec Commences Mailing of Proxy Materials to Shareholders. Biogen Idec: Cambridge, MA, 8 May 2008; http://investor.biogenidec.com/phoenix. zhtml?c=148682&p=irol-newsArticle&ID=1142538&highlight=.
14. Top 10 Profit Margins by Industry. The Online Investor: 29th December 2009; www.theonlineinvestor.com/en/stock-research/top-10-profit- margins.
15. Average Cost to Develop a New Biotechnology Product Is $1.2 Billion. Tufts Center for the Study of Drug Development: Boston, MA, 9 November 2006; http://csdd.tufts.edu/NewsEvents/NewsArticle.asp?newsid=69.
16. The European Biosimilars Market: Trends and Key Success Factors. Frost and Sullivan: San Antonio, TX, 27 October 2008; http://scicasts.com/ specialreports/9-bio-it-a-biotechnology/2152-the-european-biosimilars-market- trends-and-key-success-factors.